Antagonists of the system L neutral amino acid transporter (LAT) promote endothelial adhesivity of human red blood cells

Thromb Haemost. 2017 Jun 28;117(7):1402-1411. doi: 10.1160/TH16-05-0373. Epub 2017 Apr 6.

Abstract

The system L neutral amino acid transporter (LAT; LAT1, LAT2, LAT3, or LAT4) has multiple functions in human biology, including the cellular import of S-nitrosothiols (SNOs), biologically active derivatives of nitric oxide (NO). SNO formation by haemoglobin within red blood cells (RBC) has been studied, but the conduit whereby a SNO leaves the RBC remains unidentified. Here we hypothesised that SNO export by RBCs may also depend on LAT activity, and investigated the role of RBC LAT in modulating SNO-sensitive RBC-endothelial cell (EC) adhesion. We used multiple pharmacologic inhibitors of LAT in vitro and in vivo to test the role of LAT in SNO export from RBCs and in thereby modulating RBC-EC adhesion. Inhibition of human RBC LAT by type-1-specific or nonspecific LAT antagonists increased RBC-endothelial adhesivity in vitro, and LAT inhibitors tended to increase post-transfusion RBC sequestration in the lung and decreased oxygenation in vivo. A LAT1-specific inhibitor attenuated SNO export from RBCs, and we demonstrated LAT1 in RBC membranes and LAT1 mRNA in reticulocytes. The proadhesive effects of inhibiting LAT1 could be overcome by supplemental L-CSNO (S-nitroso-L-cysteine), but not D-CSNO or L-Cys, and suggest a basal anti-adhesive role for stereospecific intercellular SNO transport. This study reveals for the first time a novel role of LAT1 in the export of SNOs from RBCs to prevent their adhesion to ECs. The findings have implications for the mechanisms of intercellular SNO signalling, and for thrombosis, sickle cell disease, and post-storage RBC transfusion, when RBC adhesivity is increased.

Keywords: S-nitrosothiol; Transfusion; cysteine; erythrocyte; nitric oxide.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Amino Acid Transport System L / antagonists & inhibitors*
  • Amino Acid Transport System L / blood*
  • Amino Acid Transport System L / genetics
  • Amino Acids, Cyclic / pharmacology
  • Animals
  • Benzoxazoles / pharmacology
  • Cell Adhesion / drug effects
  • Cell Adhesion / physiology
  • Cysteine / analogs & derivatives
  • Cysteine / pharmacology
  • Endothelial Cells / drug effects
  • Endothelial Cells / physiology*
  • Erythrocyte Deformability / drug effects
  • Erythrocyte Deformability / physiology
  • Erythrocytes / drug effects*
  • Erythrocytes / physiology*
  • Human Umbilical Vein Endothelial Cells
  • Humans
  • In Vitro Techniques
  • Leucine / pharmacology
  • Mice
  • Mice, Nude
  • RNA, Messenger / blood
  • RNA, Messenger / genetics
  • Reticulocytes / physiology
  • S-Nitrosothiols / blood
  • S-Nitrosothiols / pharmacology
  • Tyrosine / analogs & derivatives
  • Tyrosine / pharmacology

Substances

  • 2-amino-3-(4-((5-amino-2-phenylbenzo(d)oxazol-7-yl)methoxy)-3,5-dichlorophenyl)propanoic acid
  • Amino Acid Transport System L
  • Amino Acids, Cyclic
  • Benzoxazoles
  • RNA, Messenger
  • S-Nitrosothiols
  • 2-aminobicyclo(2,2,1)heptane-2-carboxylic acid
  • Tyrosine
  • S-nitrosocysteine
  • Leucine
  • Cysteine